BioCardia Return on Equity (ROE) Growth & History (BCDA)

BioCardia's return on equity was −950.12% for fiscal 2025.

View full BioCardia company overview

BioCardia annual return on equity history

BioCardia annual return on equity

Fiscal yearPeriod endedReturn on equityChange (percentage points)
20252025-12-31−950.12%
20232023-12-31−703.62%−547.63 pp
20222022-12-31−155.98%−70.55 pp
20212021-12-31−85.43%+53.84 pp
20202020-12-31−139.27%+338.14 pp
20192019-12-31−477.41%−289.88 pp
20182018-12-31−187.53%−109.90 pp
20172017-12-31−77.64%+42.67 pp
20162016-12-31−120.30%
20132013-12-310.14%−2.18 pp
20122012-12-312.32%−116.54 pp
20112011-12-31118.87%

BioCardia return on equity trends

Over the last five fiscal years, BioCardia's return on equity decreased from −139.27% to −950.12%, a change of −810.84 percentage points. The latest reported quarter, Q2 2026, shows −197.43%.

About the metric

What return on equity (ROE) means

Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.

Calculation and source

How return on equity is calculated

TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review BioCardia source filings ↗

Community posts

It’s quiet here.

No posts about BCDA yet. Start the conversation.

Write the first post